Effectiveness of a nurse practitioner-led cardiovascular prevention clinic at reduction of metabolic syndrome following maternal complications of pregnancy: a preliminary analysis

Emily Aldridge¹,²,³*, Maleesa Pathirana¹,², Melanie Wittwer¹,³, Susan Sierp³, Shalem Y. Leemaqz⁴, Claire T. Roberts¹,²,⁴, Gustaaf A. Dekker¹,²,⁵ and Margaret A. Arstall¹,³

Abstract
Aim: Maternal complications of pregnancy, including hypertensive disorders of pregnancy, gestational diabetes mellitus, intrauterine growth restriction, preterm labour, and placental abruption, are associated with increased risk of future cardiometabolic disease. Lifestyle interventions that focus on preventative strategies for this young, high-risk population of women may assist in cardiometabolic disease risk reduction. The aim of this preliminary registry analysis was to observe the change in maternal metabolic syndrome status after receiving a nurse practitioner-led lifestyle intervention delivered soon after a complicated pregnancy.

Method: This preliminary analysis included 64 eligible women who had attended both baseline (approximately 6 months postpartum) and review (approximately eighteen months postpartum) appointments at the postpartum lifestyle clinic after an index pregnancy complicated by at least one maternal complication of pregnancy. Metabolic syndrome status at both appointments was assessed.

Results: At the baseline appointment, 22 (34.4%) women met the criteria for metabolic syndrome. This number reduced at the review appointment to 19 (29.7%). This difference was not statistically significant. There were some modest improvements in the individual cardiometabolic risk factors, as well as marked improvements in the women who had recovered from metabolic syndrome over twelve months.

Conclusion: There was a high percentage of metabolic syndrome present early in the postpartum period. The results of this preliminary analysis highlight the importance of continuing preventative care and ongoing research for this group of high-risk women.

Keywords: Metabolic syndrome, Cardiovascular disease prevention, Pregnancy complications, Maternal health

Introduction
Certain complications of pregnancy, including hypertensive disorders of pregnancy, gestational diabetes mellitus, intrauterine growth restriction, spontaneous preterm labour, and placental abruption, affect one quarter of all pregnancies in Australia [1] and are associated with
a significantly increased maternal risk of cardiovascular and metabolic disease in later life [2–10]. Pregnancy provides a unique opportunity to identify young women at risk of cardiometabolic disease, and the early postpartum period is an ideal time to introduce primary prevention strategies as women are already engaged with the healthcare system.

Recommendations for monitoring women with a previous history of a complication of pregnancy have been published for over a decade [11, 12], yet availability of these services and patient uptake remains relatively low. The first and most notable standardised postpartum prevention clinical model is the Maternal Health Clinic in Kingston, Canada [13] which, since its inception in 2011, has been replicated in other locations across Canada and the world. An analysis of clinic attendance between pregnancies and subsequent pregnancy outcomes found that attendance at the Maternal Health Clinic was associated with lower inter-pregnancy weight gain and fewer diagnoses of type 2 diabetes [14]. However, the true effectiveness of this clinic at reducing cardiovascular risk long-term has yet to be investigated. In Australia, there are very few postpartum follow-up services for this high-risk cohort. In 2018, the first nurse-practitioner led postpartum lifestyle clinic was introduced at a metropolitan hospital based in the northern suburbs of Adelaide, South Australia [15]. This outpatient service was developed using the Maternal Health Clinic clinical model and provides cardiometabolic risk screening and individualised lifestyle and risk reduction education for all women who experience a serious complication of pregnancy. The effectiveness of this clinic is also yet to be assessed.

The effectiveness of lifestyle interventions at reducing cardiometabolic risk in women following a complicated pregnancy has not been thoroughly explored, primarily due to the fact that these services are relatively new and target a young population of women who have not yet reached an age where cardiovascular events would be expected to occur. The true long-term effectiveness of postpartum preventative strategies at reducing the incidence of major adverse cardiovascular events may therefore remain unknown for some years to come. Accurately assessing cardiovascular and metabolic risk in younger women in general is made difficult by ineffective traditional cardiovascular risk calculators which underestimate absolute risk in women and young people, and do not take into account pregnancy history [16].

Metabolic syndrome, a cluster of the most dangerous heart attack risk factors, is associated with a 4-fold increased risk of developing cardiovascular disease in women [17] and is a preclinical marker of risk in younger patients. Recovery from metabolic syndrome is significantly associated with a decreased risk for major adverse cardiovascular events, providing clear clinical targets for improvement [18]. Metabolic syndrome is detectable in younger cohorts and may therefore be a useful surrogate for absolute cardiovascular risk in young women, and has been assessed in a number of previous studies of maternal health following pregnancy complications [19–24]. In a preliminary analysis of our cohort at 6 months postpartum, metabolic syndrome was present in 36% of women [25].

The aim of this study was to assess the percentage change in metabolic syndrome over time in a cohort of women with a history of a complication of pregnancy who attended the postpartum lifestyle clinic. It was hypothesised that there would be a lower overall percentage of metabolic syndrome at approximately eighteen months postpartum review compared with that at 6 months postpartum.

**Methods**

**Study design and setting**

This was a prospective observational study of the postpartum lifestyle clinic at the Lyell McEwin Hospital (LMH) [15]. The LMH is a public tertiary acute-care facility providing obstetric care, adult cardiac and intensive care services, and neonatal care for infants at ≥ 32 weeks’ gestation and located within the Northern Adelaide Local Health Network (NALHN), South Australia. The NALHN area is characterised by a population with low socioeconomic status with high rates of CVD morbidity and mortality, and is among Australia’s most disadvantaged suburban communities [26]. The Central Adelaide Local Health Network Human Research Ethics Committee approved the study [HREC/16/TQEH/258].

**The postpartum lifestyle intervention clinic**

Methods for the hospital-based outpatient clinical service and associated quality assurance registry have been previously described [15]. Briefly, to be eligible for referral to the postpartum lifestyle clinic, women must have experienced at least one of the following complications in their index pregnancy: hypertension disorder of pregnancy requiring medical therapy or resulting in birth < 37 weeks’ gestation, gestational diabetes mellitus requiring metformin or insulin therapy, spontaneous preterm labour < 34 weeks’ gestation, intrauterine growth restriction or delivery of a small for gestational age infant at < 5th customised birth centile, or placental abruption. At approximately 6 months postpartum, participants undergo a thorough baseline health assessment and receive individualised health counselling from an expert nurse practitioner. Variables are collected from a combination of patient self-report and abstraction from the hospital medical record. Information collated and
included in the registry includes patient demographics, medical history, family history, current medications, alcohol, drug and smoking practices, obstetric history, cardiovascular and metabolic screening pathology results, systolic and diastolic blood pressures, height, weight, and waist circumference. Blood pressure was measured using an oscillometric pulse wave analysis device, the USCOM BP+ [USCOM, Sydney, Australia]. This device has been previously validated against aneroid blood pressure measurements [27]. A review appointment is conducted at 18 months postpartum where all study measures are repeated.

Following collection of the clinical and demographic information, the nurse practitioner provides individualised health and lifestyle education and clinical counseling aiming to improve modifiable cardiovascular risk factors. General dietary advice based on the Australian Heart Foundation Heart Healthy Eating Patterns position statement and Australian Dietary Guidelines is provided [28, 29]. Broadly, these guidelines recommend eating plenty of fruit, vegetables and whole grains, a variety of heart-healthy protein sources and limiting the intake of red meat, consuming healthy dairy choices (and choosing reduced-fat dairy if blood cholesterol is high), choosing healthy fat sources, and using herbs and spices in the place of salt. Physical activity advice is provided to women in alignment with Australia's Physical Activity and Sedentary Behaviour Guidelines (18–65 years) and the Australian Heart Foundation exercise guidelines [30, 31], which recommend at least 30 min of daily exercise and incorporating a combination of aerobic and muscle-strengthening exercises. Additional investigations may be ordered where necessary, and referrals to medical specialists or other services are made where appropriate. A formal report summarising patient results are forwarded to the nominated general practitioner.

**Study inclusion/exclusion criteria**

Women who attended both the baseline and review appointments at the postpartum clinic from 7th August 2018 to 14th July 2021 were included. Women who were pregnant at either baseline or review appointment, did not complete pathology testing, or did not attend their review appointment, were excluded as metabolic syndrome status could not be accurately determined.

**Outcomes**

The primary outcome of interest for this study was the reduction in percentage of metabolic syndrome from baseline to review. This change in percentage was considered a surrogate measure for the effectiveness of the intervention delivered at baseline.

Metabolic syndrome was defined as the presence of any 3 of the following five risk factors [32]:

- Elevated waist circumference with ethnicity specific values defined by the International Diabetes Federation [33], which for women is ≥ 80 cm for all ethnicities
- Elevated triglycerides of ≥ 1.7 mmol/L, or drug treatment for this lipid abnormality
- Reduced HDL cholesterol of < 1.3 mmol/L, or drug treatment for this lipid abnormality
- Elevated systolic blood pressure of ≥ 130 mmHg and/or diastolic blood pressure of ≥ 85 mmHg, or antihypertensive drug treatment
- Elevated fasting glucose of ≥ 5.6 mmol/L, or drug treatment of elevated glucose.

Secondary outcomes in this study included individual cardiovascular and metabolic risk factors, such as waist circumference, body mass index, peripheral systolic and diastolic blood pressures, triglycerides, HDL cholesterol, fasting plasma glucose, fasting insulin, and smoking status.

**Analysis**

Continuous variables are presented as mean and standard deviation and categorical data are presented as count and percentage. Values were rounded to the nearest 2 decimal places. McNemar's test was conducted to assess the difference between metabolic syndrome status at the 2 time points. Paired t-tests were used to assess the mean differences in continuous variables between the 2 time points. The change in metabolic syndrome status from baseline to review was categorised into 4 groups (no metabolic syndrome at either timepoint, metabolic syndrome at both timepoints, metabolic syndrome at first timepoint but not at second timepoint, and no metabolic syndrome at first timepoint but development of metabolic syndrome at second timepoint), and descriptive statistics of the change in cardiometabolic risk factors for each group were reported. Further analysis to assess the risk of metabolic syndrome status at review was undertaken using binary logistic regression with backwards stepwise elimination, adjusting for metabolic syndrome status at baseline, age, parity, ethnicity and socioeconomic status. All analyses were conducted using IBM SPSS Statistics for Windows, version 28.0 (Armonk, NY: IBM Corp).

**Results**

The number and proportion of eligible women included in this study was 64 (40.5%) out of a possible 158. The inclusion and participation information
is displayed in Fig. 1. The average time from referral to the first appointment was 7.5 ± 1.9 months, and the average time between the first appointment and the review appointment was 14 ± 3.9 months. None of the women had an intervening pregnancy between the appointments.

Participant demographics at the time of first appointment are displayed in Table 1. Majority of participants were married or in de facto relationships (90.7%), spoke English as their preferred language (81.2%) and had experienced gestational diabetes (68.8%) in their index pregnancy. The mean age of the cohort was 33 years. The average number of children for each participant was 2, and the range of parity was 1–6.

Table 2 shows metabolic syndrome status and cardiometabolic risk factors for the cohort at both baseline and follow-up. There were no statistically significant differences between time points, although there were minor reductions in the percentage of the cohort with metabolic syndrome and mean waist circumference, systolic blood pressure, lipids, glucose, and insulin at review.

Looking more in depth at the change in metabolic syndrome status over time, 79.7% of the cohort presented with the same metabolic syndrome status at review as baseline (no metabolic syndrome at either timepoint, 57.8%; metabolic syndrome at both timepoints, 21.9%). Of note, 12.5% of the cohort had metabolic syndrome at baseline but no longer met the criteria at review; conversely, 7.8% did not have metabolic syndrome at baseline but had developed it by the time of review. The mean changes in cardiometabolic risk factors are presented in Table 3.

A binary logistic regression was conducted with backwards stepwise elimination to further explore the risk of metabolic syndrome at review, adjusting for metabolic syndrome status at baseline, age, parity, ethnicity, and socioeconomic status. Based on the probability criteria (F-to-enter = 0.05 and F-to-remove = 0.10), ethnicity and socioeconomic status were eliminated from the model, with age and parity remaining as variables of interest. For every additional year in age, there was a 12.7% increase in odds of meeting metabolic syndrome criteria at review (adjusted odds ratio (aOR): 1.13, 95% confidence interval (CI) 0.98, 1.30; p = 0.10), although this was not statistically significant. For every additional child born to a participant, there was 28.6% decreased odds of having metabolic syndrome at review (aOR: 0.71, 95% CI 0.40, 1.27; p = 0.25), although also not statistically significant. The odds of having metabolic syndrome at review were more than 15 times lower for participants who had more than one child compared to those who had only one child.
higher if metabolic syndrome was present at baseline (aOR: 15.85, 95% CI 3.99, 63.09; p < 0.001).

Table 2 Metabolic syndrome status and risk factors at baseline and review, n = 64

| Metabolic syndrome present, n (%) | Baseline | Review | p-value |
|----------------------------------|----------|--------|---------|
| MetS at both time points          | 22 (34.4)| 19 (29.7)| 0.58 |
| MetS at second timepoint          | 20 (31.3)| 17 (26.6)|    |
| MetS at first timepoint but did not meet criteria at second timepoint | 2 (3.1)| 2 (3.1)|    |
| Developed MetS during study       | 0 (0.0)| 1 (1.6)|    |

Number of metabolic syndrome criteria present

| Criteria | Baseline | Review | p-value |
|----------|----------|--------|---------|
| 0        | 6 (9.4)  | 7 (10.9)|        |
| 1        | 16 (25.0)| 16 (25.0)|     |
| 2        | 19 (29.7)| 22 (34.4)|    |
| 3        | 14 (21.9)| 11 (17.2)|    |
| 4        | 8 (12.5)| 7 (10.9)|    |
| 5        | 0 (0.0)  | 1 (1.6)|    |

BMI, kg/m² 30.27 ± 7.09 30.40 ± 7.38 0.31
Waist circumference, cm 95.24 ± 14.99 95.11 ± 14.56 0.23
Peripheral SBP, mmHg 122.22 ± 13.12 120.97 ± 12.73 0.11
Peripheral DBP, mmHg 73.09 ± 10.57 73.11 ± 11.67 0.49
Triglycerides, mmol/L 1.37 ± 0.93 1.27 ± 0.71 0.18
HDL cholesterol, mmol/L 1.28 ± 0.28 1.25 ± 0.30 0.18
Glucose, mmol/L 5.20 ± 1.20 5.15 ± 0.77 0.44
Insulin, mU/L 15.22 ± 15.54 12.22 ± 7.69 0.09
HOMA-IR 3.54 ± 3.72 2.84 ± 1.99 0.24
Medicated hypertension 4 (6.3) 6 (9.4)
Medicated T2DM 1 (1.6) 2 (3.1)
Current smoking 6 (9.4) 7 (10.9)

BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure, HDL: high-density lipoprotein, HOMA-IR: Homeostatic Model Assessment for Insulin Resistance, T2DM: type 2 diabetes mellitus

Discussion

This study aimed to observe the change in metabolic syndrome status between two time points in a cohort of women referred to the postpartum lifestyle clinical. Overall, we saw a modest reduction of 4.7% in the percentage of the cohort with metabolic syndrome at review compared to baseline, but this was not statistically significant. There were also small but not statistically significant improvements at time of review for the mean values of peripheral systolic blood pressure, triglycerides, HDL cholesterol, glucose, and insulin, and the number of current smokers reduced by one participant (16.7%). Although mean BMI slightly increased from baseline to review, this was not reflected in the waist circumference measurements, which slightly reduced.

Over half of the study cohort (57.8%) did not have metabolic syndrome at either time point, which is promising for future cardiometabolic health if this persists long-term. However, 91.6% and 89.1% of the entire cohort had at least one criterion for metabolic syndrome at baseline and review, respectively. Of the patients with metabolic syndrome at baseline, 8 (36%) recovered and did not meet the criteria at review. There was an overall mean improvement in all of the cardiometabolic risk factors, with the most notable change being observed in the mean fasting insulin levels (Table 3). This could indicate that these participants may have benefited from the postpartum lifestyle clinic and taken steps to reduce their cardiometabolic risk. However, 5 (7.8%) participants did not have metabolic syndrome at baseline but did meet the criteria at review. Over 20% of the cohort had metabolic syndrome at both time points. It is possible that the intervention may not have been effective for

Table 3 Mean change in cardiometabolic risk factors over time

| Risk factor          | No MetS at either time point, n = 37 | MetS at first timepoint, no MetS at second timepoint (MetS resolved), n = 8 | No MetS at either time point, n = 14 | Developed MetS during study: MetS at first timepoint, n = 5 |
|----------------------|-------------------------------------|------------------------------------------------|-------------------------------------|----------------------------------------------------------|
| BMI, kg/m²            | 0.31 ± 2.40                         | −0.87 ± 2.63                                   | 0.29 ± 1.49                         | 0.08 ± 1.42                                                |
| Waist circumference, cm | −0.21 ± 12.88                       | −3.71 ± 4.22                                   | 0.39 ± 5.52                         | −0.02 ± 2.94                                               |
| Peripheral SBP, mmHg  | −4.57 ± 19.90                       | −3.12 ± 8.22                                   | −1.64 ± 11.00                       | 3.20 ± 6.65                                                |
| Peripheral DBP, mmHg  | −2.54 ± 14.67                       | −1.38 ± 9.97                                   | 1.21 ± 8.67                         | 3.20 ± 9.26                                                |
| Triglycerides, mmol/L | −0.09 ± 0.78                        | −0.45 ± 0.67                                   | 0.12 ± 0.77                         | 0.32 ± 0.25                                                |
| HDL cholesterol, mmol/L | 0.54 ± 0.41                        | 0.10 ± 0.19                                    | −0.50 ± 0.13                        | 0.40 ± 0.27                                                |
| Glucose, mmol/L       | 0.22 ± 1.97                         | −0.20 ± 1.21                                   | 0.41 ± 1.80                         | 0.44 ± 0.89                                                |
| Insulin, mU/L         | −1.44 ± 16.16                       | −1.28 ± 16.44                                  | 1.10 ± 10.69                        | −0.42 ± 8.26                                               |
| HOMA-IR               | −0.39 ± 3.66                        | −3.26 ± 5.02                                   | 0.34 ± 3.56                         | 0.15 ± 2.32                                                |

Data are presented as mean ± standard deviation. 'Improves' denotes those who had MetS at the first time point but did not meet the criteria at the second time point. 'No change' denotes those who had MetS at both time points. 'Worse' denotes those who did not have MetS at the first time point but met the criteria at the second time point.

MetS: metabolic syndrome, BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure, HDL: high-density lipoprotein, HOMA-IR: Homeostatic Model Assessment for Insulin Resistance.
these participants, or perhaps that it was not effective within the study timeframe. The number of participants medicated for hypertension or type 2 diabetes increased from baseline by 1 and 2 participants, respectively. This may suggest an important role of the postpartum lifestyle clinic for identifying patients who need medical therapy after typical postpartum follow-up with general practitioners has ceased.

The percentage of metabolic syndrome at both time points is higher than that reported in other similar studies. A preliminary analysis of our registry cohort at 7 months postpartum found 36% of women had metabolic syndrome [25], higher than the rate reported at baseline in the present study. In a recent comparison of Maternal Health Clinic data with data from a similar clinic in rural Canada, metabolic syndrome prevalence at 6 months postpartum was 21.8% and 29.2%, respectively [34]. These values are lower than the metabolic syndrome prevalence reported at baseline in the current study (34.4%), which may be attributed to the high levels of socioeconomic disadvantage in the area in which our postpartum lifestyle clinic operates. This may also be a reflection of including only medicated or severe cases of the complications of pregnancy in the postpartum lifestyle clinic.

In general, lifestyle interventions have been found to be effective at reducing metabolic syndrome and other cardiometabolic risk factors. A study of adults with metabolic syndrome found that a lifestyle intervention incorporating dietary, exercise and behaviour modification education sessions significantly reduced metabolic syndrome by 72%, central obesity by 67%, the incidence of diabetes by 77% and hypertriglyceridemia by 52% after 12 months [35]. It is important to note, however, that this included a relatively intensive intervention with multiple individual and group sessions, compared with general practitioner advice. The study also focused on middle-aged adults, and not on new mothers. Analyses of the long-term effectiveness of lifestyle interventions, specifically those delivered in the postpartum period, at reducing cardiometabolic disease have not yet been able to be performed due to the length of time required for follow-up. Preliminary results reported in the literature are varied, but positive. A systematic review found that lifestyle interventions of exercise, dietary habits, and smoking cessation are associated with an estimated 4–13% decreased cardiovascular risk after preeclampsia [36]. However, this 2013 review included studies that are now ≥ 15 years old, and cardiovascular risk in almost every study was determined using risk prediction models based on cohorts of mostly older men. The length of follow-up of the studies was also far less than the time span of the cardiovascular risk prediction models [36]. A systematic review of the effectiveness of both technology-based and face-to-face lifestyle interventions at preventing type 2 diabetes in women with a history of gestational diabetes reported that most interventions improved insulin resistance-related and weight-related measures in the short-term, but indicated the long-term effectiveness of these interventions needs further research [37].

Currently, the participants in our cohort receive face-to-face counselling appointments at the clinic at approximately 6 months and eighteen months, with a plan to also review them at 5 years postpartum, with no contact between appointments. Participants also have the option to be referred through the clinic to a free telephone counselling service that provides ongoing dietary and exercise advice. A focus group study of women with a history of preeclampsia, gestational diabetes, or intrauterine growth restriction reported that women found adopting a healthy lifestyle after delivery extremely difficult and that they lacked professional support and guidance to facilitate lifestyle change [38]. It is possible that we need to increase the level of support provided to our participants to see more marked effectiveness. A study by Berks and colleagues found improved cardiometabolic risk factors over seven months of an intervention involving multiple individual counselling sessions and a computer health education program [39]. Furthermore, a dietitian-led intervention for women with gestational diabetes commencing during pregnancy and continuing until seven months postpartum and focusing on diet, exercise, and breastfeeding practices showed some improvements in weight reduction, although this was not statistically significant [40]. Further qualitative research is warranted to identify the ideal frequency and mode of contact with the postpartum lifestyle clinic to maximise effectiveness.

Limitations

There are a number of limitations in the present study that warrant discussion. This was a preliminary analysis of an ongoing study, and therefore the study was limited by a small sample size. Multinomial logistic regressions to examine the effects of age and parity on the change of metabolic syndrome status over time were not able to be performed due to the small study size. However, preliminary analyses are necessary to establish a baseline of expected results and allows for optimisation of methods if needed. Metabolic syndrome status prior to pregnancy was not able to be assessed, and so it is possible that metabolic syndrome had persisted in some women for a long period of time and pre-dated their pregnancy complication. There was no control group that had not received the intervention, so conclusions about the true effectiveness of
the intervention are not able to be made. However, the results of this study provide rationale and preliminary data for conducting a fully powered randomised controlled trial to assess the intervention's effectiveness at reducing metabolic syndrome and overall cardiometabolic risk.

Our study is inherently limited by self-selection bias, as one-third of the participants who attended a baseline appointment did not attend a review appointment. This is likely to be a result of a combination of the following factors: (1) general loss of follow-up due to address and phone number changes, (2) administration errors, (3) attendance hesitancy due to COVID-19 pandemic, (4) inability to attend an appointment on the designated clinic days and times, or due to time constraints. Further research exploring the barriers to attendance are required. No participants referred to the clinic for preterm labour or placental abruption were eligible to be included in this study, and there was a high rate of gestational diabetes in the cohort. It is likely that future analyses from this ongoing study will be able to incorporate a wider range of participants and those with the rarer complications of pregnancy, such as spontaneous preterm labour and placental abruption.

Finally, we did not assess the effectiveness of the intervention on the outcomes of any subsequent pregnancies. A recent retrospective analysis of more than 66,000 singleton pregnancies found that achieving optimal weight gain during pregnancy significantly reduced development of late-onset preeclampsia in overweight or obese women (OR 0.42, p < 0.0001) [41], supporting the potential role of lifestyle intervention prior to or during pregnancy to assist in weight management. A recent study of women with an index pregnancy complicated by gestational diabetes or a hypertensive disorder found that attendance at the Maternal Health Clinic was associated with inter-pregnancy weight reduction, fewer inter-pregnancy diagnoses of type 2 diabetes, and delivery of subsequent pregnancy at a later gestational age [14]. A meta-analysis of lifestyle interventions delivered during pregnancy also found that dietary interventions reduced the risk of preeclampsia by 33% when compared to controls [42]. However, a more recent randomised control trial of healthy weight women found that lifestyle intervention had no impact on development of any maternal complications of pregnancy [43]. Another study of overweight or obese women recruited early in pregnancy found that diet and exercise advice had no impact on (1) cardiometabolic inflammatory markers, including glucose, HDL cholesterol, triglycerides, and insulin, at multiple time points during pregnancy [44], and (2) development of maternal complications of pregnancy [45]. Future research exploring the effect, if any, of our postpartum lifestyle clinic on subsequent pregnancies should be conducted.

**Conclusion**

The results of this preliminary analysis confirmed a high rate of metabolic syndrome in an early postpartum cohort of women who had recently experienced a complication of pregnancy. The study showed a modest improvement in the overall prevalence of metabolic syndrome at review compared to baseline. There were also some minor improvements in individual cardiometabolic risk factors over time. These results highlight the importance of continuing preventative care for this high-risk group of women. Future research will examine the effectiveness of our nurse practitioner-led lifestyle intervention at reducing metabolic syndrome through a fully powered randomised controlled trial.

**Acknowledgements**

Not applicable.

**Author contributions**

EA designed the study, collected the data, performed data analysis, and prepared the manuscript. MP and SS assisted with data collection. SYL provided statistical analysis support. CTR, GAD and MAA supervised the study. All authors edited the draft manuscript, provided critical feedback, and approved the final manuscript. All author read and approved the final manuscript.

**Funding**

This study received no specific funding. EA was supported by a fellowship grant awarded by The Hospital Research Foundation (Grant ID 2018/006-QA25232). CTR was supported by a NHMRC Investigator Grant (GNT1174971) and a Matthew Flinders Fellowship from Flinders University.

**Availability of data and materials**

The datasets generated and/or analysed during the current study are not publicly available due local ethical regulations and privacy principles but are available from the corresponding author on reasonable request and with permission of local ethics committees.

**Declarations**

**Ethics approval and consent to participate**

The Central Adelaide Local Health Network Human Research Ethics Committee approved the study (HREC/16/TQEH/258) and waived the requirement for written informed consent.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no conflicts of interests.

**Author details**

1 Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia. 2 Robinson Research Institute, University of Adelaide, Haydown Road, Elizabeth Vale, Adelaide, South Australia, Australia. 3 Department of Cardiology, Northern Adelaide Local Health Network, Elizabeth Vale, Adelaide, South Australia, Australia. 4 Flinders Health and Medical Research Institute, Flinders University, Bedford Park, South Australia, Australia. 5 Department of Obstetrics and Gynaecology, Northern Adelaide Local Health Network, Elizabeth Vale, Adelaide, South Australia, Australia.
References

1. Australian Institute of Health and Welfare. Australia’s mothers and babies 2018: in brief. perinatal statistics series no. 36. Canberra: 2020. https://www.aihw.gov.au/reports/mothers-babies/australias-mothers-babies/contents/about.

2. Wu P, Hathothuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, et al. Pre-eclampsia and future cardiovascular health: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2017. https://doi.org/10.1161/CIRCOUTCOMES.116.003497.

3. Wu P, Kwok CS, Hathothuwa R, Kotronias RA, Babu A, Fryer AA, et al. Pre-eclampsia is associated with a twofold increase in diabetes: a systematic review and meta-analysis. Diabetologia. 2016;59:2518–26. https://doi.org/10.1007/s00125-016-4098-x.

4. Wu P, Gulati M, Kwok CS, Wong CW, Nairin A, O’Brien S, et al. Preterm delivery and future risk of maternal cardiovascular disease: a systematic review and meta-analysis. J Am Heart Assoc. 2018. https://doi.org/10.1161/JAHA.117.007809.

5. Andraweera PH, Dekker GA, Arstall M, Bianco-Miotto T, Roberts CT. Complications of pregnancy and future cardiovascular risk. In: Sawary DB, Vasan RS, editors. Encyclopedia of Cardiovascular Research and Medicine. Amsterdam: Elsevier; 2017.

6. Ray HG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet. 2005. https://doi.org/10.1016/S0140-6736(05)6726-4.

7. Ngo AD, Roberts CL, Chen JS, Figtree G. Delivery of a small-for-gestational-age infant and risk of maternal cardiovascular disease—a population-based record linkage study. Hear Lung Circ. 2013;5:696–704. https://doi.org/10.1016/j.hlcc.2015.01.004.

8. DeFeo L, Skjærven R, Wilcox A, Klungsøyr K, Wikström AK, Morken NH, et al. Placental abruptio and long-term maternal cardiovascular disease mortality: a population-based registry study in Norway and Sweden. Eur J Epidemiol. 2016;31:501–11. https://doi.org/10.1007/s10654-015-0697-9.

9. Neiger B. Long-term effects of pregnancy complications on maternal health: a review. J Clin Med. 2017. https://doi.org/10.3390/jcm6080076.

10. Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis. Diabetologia. 2019;62:905–14. https://doi.org/10.1007/s00125-019-4840-2.

11. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update a guideline from the american heart association. J Am Coll Cardiol. 2011;57:1404–23. https://doi.org/10.1016/j.jacc.2011.02.026.

12. Beigzadzadek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart JM, et al. ESC guidelines on the management of cardiovascular disease in women-2011 update a guideline from the american heart association. J Am Coll Cardiol. 2011;57:1404–23. https://doi.org/10.1016/j.jacc.2011.02.026.

13. Smith GN, Pudwel J, Walker M, Wen SW. Risk estimation of metabolic syndrome at one and three years after a pregnancy complicated by pre-eclampsia. J Obest Gynaecol Canada. 2012;34:836–41. https://doi.org/10.1016/j.jogc.2011.07.018.

14. Hermes W, Franx A, Van Pampus MG, Bloemenkamp KWM, Bots ML, Van Der Post JA, et al. Cardiovascular risk factors in women who had hyper-tensive disorders late in pregnancy: a cohort study. Am J Obest Gynecol. 2013;208:4471–4478. https://doi.org/10.1016/j.ajog.2013.02.016.

15. Aldridge E, Pathirana M, Wittmer M, Sierp S, Leemans SY, Roberts CT, et al. Prevalence of metabolic syndrome in women after maternal complications of pregnancy: an observational cohort analysis. Front Cardiovasc Med. 2022. https://doi.org/10.3389/fcvm.2022.853851.

16. Heart Foundation Australia. cardiovascular disease map by South Australian local health network n.d. https://www.heartfoundation.org.au/assets/HeartMaps/SouthAust/ln-map/StatPlanet.html.

17. Aldridge E, Pathirana M, Wittmer M, Dekker G, Roberts CT, et al. Agreement of aneroid and oscillometric blood pressure devices used in pregnancy. Hypertens. 2019;17:43–8. https://doi.org/10.1136/heartjnl-2019-050.005.

18. Heart Foundation Australia. Heart Healthy Eating Patterns Dietary Position Statement. 2019. https://www.heartfoundation.org.au/bundles-for-professionals/nutrition-position-statements.

19. National Health and Medical Research Council. Recommended number of serves for adults | Eat For Health. Natl Heal Med Res Counc 2015. https://www.eatforhealth.gov.au/food-essentials/how-much-do-we-eat/30-serves-for-adults.

20. Australian Government Department of Health. Australia’s Physical Activity and Sedentary Behaviour Guidelines for Adults (18–64 years) 2014. https://www1.health.gov.au/internet/main/publishing.nsf/content/health-pubhlth-strateg-phys-act-guidelines#npa1864.

21. Heart Foundation Australia. Get active | The Heart Foundation 2014. https://www.heartfoundation.org.au/active-living/get-active (accessed November 22, 2019).

22. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation international. Circulation. 2009;120:1640–5. https://doi.org/10.1161/CIRCULATIONAHA.109.192844.

23. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Brussels: 2006. https://www.idf.org/e-library/consensus-statements/60-idfc consensus-worldwide-definition-of-the-metabolic-syndrome.html.

24. McGrath CK, Pudwel J, Pienaar E, Pienaar M, Smith GN. Cardiovascular risk screening and pregnancy complications: a comparison of two Canadian maternal health clinic populations. J Obest Gynaecol Canada. 2021. https://doi.org/10.1016/j.jogc.2021.05.012.

25. Bo S, Ciccone G, Baldi C, Benini L, Dusio F, Forastiere G, et al. Effectiveness of a lifestyle intervention on metabolic syndrome: a randomized...
controlled trial. J Gen Intern Med. 2007;22:1695–703. https://doi.org/10.1007/s11606-007-0399-6.

36. Berks D, Hoedjes M, Raat H, Duvekot JJ, Steegers EAP, Habberma JDF. Risk of cardiovascular disease after pre-eclampsia and the effect of lifestyle interventions: a literature-based study. BJOG An Int J Obstet Gynaecol. 2013;120:924–31. https://doi.org/10.1111/1471-0528.12191.

37. Guo J, Chen JL, Whittmore R, Whitaker E. Postpartum lifestyle interventions to prevent type 2 diabetes among women with history of gestational diabetes: a systematic review of randomized clinical trials. J Women’s Heal. 2016;25:38–49. https://doi.org/10.1089/jwh.2015.5262.

38. Hoedjes M, Berks D, Vogel I, Franx A, Duvekot JJ, Oenema A, et al. Motivators and barriers to a healthy postpartum lifestyle in women at increased cardiovascular and metabolic risk: a focus-group study. Hypertens Pregnancy. 2012;31:147–55. https://doi.org/10.3109/10641955.2010.544803.

39. Berks D, Hoedjes M, Raat H, Franx A, Looman CWN, Van Oostwaard MF, et al. Feasibility and effectiveness of a lifestyle intervention after complicated pregnancies to improve risk factors for future cardiometabolic disease. Pregnancy Hypertens. 2019;15:98–107. https://doi.org/10.1016/j.preghy.2018.12.004.

40. Ferrara A, Hedderson MM, Albright CL, Ehrlich SF, Quesenberry CP, Peng T, et al. A pregnancy and postpartum lifestyle intervention in women with gestational diabetes mellitus reduces diabetes risk factors: a feasibility randomized control trial. Diabetes Care. 2011;34:1519–25. https://doi.org/10.2337/dc10-2221.

41. Robillard PY, Dekker G, Boukerrou M, Boumanh B, Hulsey T, Scioscia M. Gestational weight gain and rate of late-onset preeclampsia: a retrospective analysis on 57,000 singleton pregnancies in reunion Island. BMJ Open. 2020;10:e036549. https://doi.org/10.1136/bmjopen-2019-036549.

42. Allen R, Rogozinskia E, Sivarajasingam P, Khan KS, Thangaratnam S. Effect of diet-and lifestyle-based metabolic risk-modifying interventions on preeclampsia: a meta-analysis. Acta Obstet Gynecol Scand. 2014;93:973–85. https://doi.org/10.1111/aogs.12467.

43. Dodd JM, Deussen AR, Louise J. A randomised trial to optimise gestational weight gain and improve maternal and infant health outcomes through antenatal dietary, lifestyle and exercise advice: the optimise randomised trial. Nutrients. 2019;11:2911. https://doi.org/10.3390/nu11122911.

44. Moran LJ, Fraser LM, Sundernathan T, Deussen AR, Louise J, Yelland LN, et al. The effect of an antenatal lifestyle intervention in overweight and obese women on circulating cardiometabolic and inflammatory biomarkers: secondary analyses from the LIMIT randomised trial. BMC Med. 2017. https://doi.org/10.1186/s12916-017-0790-z.

45. Dodd JM, Turnball D, McPhee AJ, Deussen AR, Grivell RM, Yelland LN, et al. Antenatal lifestyle advice for women who are overweight or obese: Limit randomised trial. BMJ. 2014. https://doi.org/10.1136/bmj.g1285.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.